Sorafenib for Patients with Advanced Angiosarcoma

The Oncologist, 02/27/2012

Sorafenib showed limited antitumor activity in pretreated patients only, for both visceral and superficial angiosarcoma, but tumor control was of short duration.

Print Article Summary Cat 2 CME Report